220 related articles for article (PubMed ID: 32130941)
21. Depletion of a putatively druggable class of phosphatidylinositol kinases inhibits growth of p53-null tumors.
Emerling BM; Hurov JB; Poulogiannis G; Tsukazawa KS; Choo-Wing R; Wulf GM; Bell EL; Shim HS; Lamia KA; Rameh LE; Bellinger G; Sasaki AT; Asara JM; Yuan X; Bullock A; Denicola GM; Song J; Brown V; Signoretti S; Cantley LC
Cell; 2013 Nov; 155(4):844-57. PubMed ID: 24209622
[TBL] [Abstract][Full Text] [Related]
22. Phosphatidylinositol-5-Phosphate 4-Kinases Regulate Cellular Lipid Metabolism By Facilitating Autophagy.
Lundquist MR; Goncalves MD; Loughran RM; Possik E; Vijayaraghavan T; Yang A; Pauli C; Ravi A; Verma A; Yang Z; Johnson JL; Wong JCY; Ma Y; Hwang KS; Weinkove D; Divecha N; Asara JM; Elemento O; Rubin MA; Kimmelman AC; Pause A; Cantley LC; Emerling BM
Mol Cell; 2018 May; 70(3):531-544.e9. PubMed ID: 29727621
[TBL] [Abstract][Full Text] [Related]
23. Discovery of (S)-2-amino-N-(5-(6-chloro-5-(3-methylphenylsulfonamido)pyridin-3-yl)-4-methylthiazol-2-yl)-3-methylbutanamide (CHMFL-PI3KD-317) as a potent and selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor.
Liang X; Li F; Chen C; Jiang Z; Wang A; Liu X; Ge J; Hu Z; Yu K; Wang W; Zou F; Liu Q; Wang B; Wang L; Zhang S; Wang Y; Liu Q; Liu J
Eur J Med Chem; 2018 Aug; 156():831-846. PubMed ID: 30053721
[TBL] [Abstract][Full Text] [Related]
24. Leveraging Compound Promiscuity to Identify Targetable Cysteines within the Kinome.
Rao S; Gurbani D; Du G; Everley RA; Browne CM; Chaikuad A; Tan L; Schröder M; Gondi S; Ficarro SB; Sim T; Kim ND; Berberich MJ; Knapp S; Marto JA; Westover KD; Sorger PK; Gray NS
Cell Chem Biol; 2019 Jun; 26(6):818-829.e9. PubMed ID: 30982749
[TBL] [Abstract][Full Text] [Related]
25. Novel drug targets in acute leukemia.
Stock W
Clin Adv Hematol Oncol; 2015 Aug; 13(8):493-5. PubMed ID: 26351809
[No Abstract] [Full Text] [Related]
26. Discovery of imidazo[1,2-a]pyridine-thiophene derivatives as FLT3 and FLT3 mutants inhibitors for acute myeloid leukemia through structure-based optimization of an NEK2 inhibitor.
Zhang L; Lakkaniga NR; Bharate JB; Mcconnell N; Wang X; Kharbanda A; Leung YK; Frett B; Shah NP; Li HY
Eur J Med Chem; 2021 Dec; 225():113776. PubMed ID: 34479037
[TBL] [Abstract][Full Text] [Related]
27. O-methylated flavonol as a multi-kinase inhibitor of leukemogenic kinases exhibits a potential treatment for acute myeloid leukemia.
Yen SC; Wu YW; Huang CC; Chao MW; Tu HJ; Chen LC; Lin TE; Sung TY; Tseng HJ; Chu JC; Huang WJ; Yang CR; HuangFu WC; Pan SL; Hsu KC
Phytomedicine; 2022 Jun; 100():154061. PubMed ID: 35364561
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of ellagic acid as an inhibitor of sphingosine kinase 1: A targeted approach towards anticancer therapy.
Gupta P; Mohammad T; Khan P; Alajmi MF; Hussain A; Rehman MT; Hassan MI
Biomed Pharmacother; 2019 Oct; 118():109245. PubMed ID: 31352240
[TBL] [Abstract][Full Text] [Related]
29. Inverse in silico-in vitro fishing of unexpected paroxetine kinase targets from tumor druggable kinome.
Zhou W; Yang H; Wang H
J Mol Model; 2020 Jul; 26(8):197. PubMed ID: 32623519
[TBL] [Abstract][Full Text] [Related]
30. Drug development: target practice.
Katsnelson A
Nature; 2013 Jun; 498(7455):S8-9. PubMed ID: 23803950
[No Abstract] [Full Text] [Related]
31. Discovery of a Small Side Cavity in Sphingosine Kinase 2 that Enhances Inhibitor Potency and Selectivity.
Sibley CD; Morris EA; Kharel Y; Brown AM; Huang T; Bevan DR; Lynch KR; Santos WL
J Med Chem; 2020 Feb; 63(3):1178-1198. PubMed ID: 31895563
[TBL] [Abstract][Full Text] [Related]
32. Sphingosine kinase inhibitors: A patent review.
Cao M; Ji C; Zhou Y; Huang W; Ni W; Tong X; Wei JF
Int J Mol Med; 2018 May; 41(5):2450-2460. PubMed ID: 29484372
[TBL] [Abstract][Full Text] [Related]
33. Discovery of Covalent MKK4/7 Dual Inhibitor.
Jiang J; Jiang B; He Z; Ficarro SB; Che J; Marto JA; Gao Y; Zhang T; Gray NS
Cell Chem Biol; 2020 Dec; 27(12):1553-1560.e8. PubMed ID: 32916088
[TBL] [Abstract][Full Text] [Related]
34. Mechanism of irreversible inhibition of Mycobacterium tuberculosis shikimate kinase by ilimaquinone.
Simithy J; Fuanta NR; Hobrath JV; Kochanowska-Karamyan A; Hamann MT; Goodwin DC; Calderón AI
Biochim Biophys Acta Proteins Proteom; 2018; 1866(5-6):731-739. PubMed ID: 29654976
[TBL] [Abstract][Full Text] [Related]
35. Recent advances in the development of sphingosine kinase inhibitors.
Pitman MR; Costabile M; Pitson SM
Cell Signal; 2016 Sep; 28(9):1349-1363. PubMed ID: 27297359
[TBL] [Abstract][Full Text] [Related]
36. Protein kinase C-δ inhibitor, Rottlerin inhibits growth and survival of mycobacteria exclusively through Shikimate kinase.
Pandey S; Chatterjee A; Jaiswal S; Kumar S; Ramachandran R; Srivastava KK
Biochem Biophys Res Commun; 2016 Sep; 478(2):721-6. PubMed ID: 27498028
[TBL] [Abstract][Full Text] [Related]
37. Structure-activity relationship studies and in vivo activity of guanidine-based sphingosine kinase inhibitors: discovery of SphK1- and SphK2-selective inhibitors.
Patwardhan NN; Morris EA; Kharel Y; Raje MR; Gao M; Tomsig JL; Lynch KR; Santos WL
J Med Chem; 2015 Feb; 58(4):1879-1899. PubMed ID: 25643074
[TBL] [Abstract][Full Text] [Related]
38. Discover Novel Covalent Inhibitors Targeting FLT3 through Hybrid Virtual Screening Strategy.
Hu S; Liu J; Chen S; Gao J; Zhou Y; Liu T; Dong X
Biol Pharm Bull; 2021; 44(12):1872-1877. PubMed ID: 34853270
[TBL] [Abstract][Full Text] [Related]
39. ULK1 inhibition as a targeted therapeutic strategy for FLT3-ITD-mutated acute myeloid leukemia.
Hwang DY; Eom JI; Jang JE; Jeung HK; Chung H; Kim JS; Cheong JW; Min YH
J Exp Clin Cancer Res; 2020 May; 39(1):85. PubMed ID: 32393312
[TBL] [Abstract][Full Text] [Related]
40. Pharmacological inhibition of PI5P4Kα/β disrupts cell energy metabolism and selectively kills p53-null tumor cells.
Chen S; Chandra Tjin C; Gao X; Xue Y; Jiao H; Zhang R; Wu M; He Z; Ellman J; Ha Y
Proc Natl Acad Sci U S A; 2021 May; 118(21):. PubMed ID: 34001596
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
